These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 11379830)
21. The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial. Nasrallah HA J Clin Psychiatry; 2007; 68 Suppl 1():5-11. PubMed ID: 17286522 [TBL] [Abstract][Full Text] [Related]
22. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. Kane JM; Leucht S; Carpenter D; Docherty JP; J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142 [TBL] [Abstract][Full Text] [Related]
24. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia. Chen H; Kennedy WK; Dorfman JH; Fincham JE; Reeves J; Martin BC Curr Med Res Opin; 2007 Jun; 23(6):1351-65. PubMed ID: 17559734 [TBL] [Abstract][Full Text] [Related]
25. Methodological and design issues in clinical trials of new neuroleptics: an overview. Awad AG Br J Psychiatry Suppl; 1993 Dec; (22):51-7. PubMed ID: 7906524 [TBL] [Abstract][Full Text] [Related]
26. [Roaming through methodology. XII. Pragmatic and pathophysiologic trials: a question of goal formulation]. Algra A; van der Graaf Y Ned Tijdschr Geneeskd; 1999 Mar; 143(10):514-7. PubMed ID: 10321260 [TBL] [Abstract][Full Text] [Related]
27. Comparison of schizophrenia drugs often favors firm funding study. Vendantam S Washington Post; 2006 Apr; ():A1, A6. PubMed ID: 16856276 [No Abstract] [Full Text] [Related]
33. [Use of certain cardiological drugs in the treatment of schizophrenia: review of the literature]. Llorca PM; Wolf MA J Psychiatry Neurosci; 1991 Mar; 16(1):19-24. PubMed ID: 1675588 [No Abstract] [Full Text] [Related]
34. Introduction to the special section: contextualizing significance testing in clinical trials. Thompson-Brenner H Psychotherapy (Chic); 2011 Sep; 48(3):215-6. PubMed ID: 21875233 [TBL] [Abstract][Full Text] [Related]
35. Commentary on 'Measurement in clinical trials: a neglected issue for statisticians?'. Wittes J Stat Med; 2009 Nov; 28(26):3220-2; discussion 3223-5. PubMed ID: 19842097 [No Abstract] [Full Text] [Related]
37. Clinical trials and tribulations: implementation processes in schizophrenia research outcome. Mason SE; Bermanzohn PC; Siris SG Psychiatry; 1998; 61(4):288-301. PubMed ID: 9919624 [TBL] [Abstract][Full Text] [Related]
38. Mixed-effect models to assess consistency and reliability across multiple evaluations. Kao TC; Sparling Y; Rochon J J Biopharm Stat; 2003 Aug; 13(3):539-48. PubMed ID: 12921400 [TBL] [Abstract][Full Text] [Related]
39. Inefficient, corrupt, and unreliable. The system for testing treatments is in chaos. Fischer J US News World Rep; 2000 Aug; 129(8):50. PubMed ID: 11066829 [No Abstract] [Full Text] [Related]
40. Missing data and convenient assumptions. Normand SL Circ Cardiovasc Qual Outcomes; 2010 Jan; 3(1):2-3. PubMed ID: 20123663 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]